Y-mAbs Therapeutics
(NASDAQ) YMAB
Y-mAbs Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$85.39M
Net Income (TTM)
$22.22M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
YMAB News
YMAB: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Y-mAbs Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
107
CEO
Michael Rossi
Website
www.ymabs.comHeadquarters
Princeton, NY 10169, US
YMAB Financials
Key Financial Metrics (TTM)
Gross Margin
82%
Operating Margin
-31%
Net Income Margin
-26%
Return on Equity
-25%
Return on Capital
-28%
Return on Assets
-19%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$72.43M
Operating Income
$31.20M
EBITDA
$30.67M
Operating Cash Flow
$15.71M
Capital Expenditure
$0.00
Free Cash Flow
$15.71M
Cash & ST Invst.
$67.23M
Total Debt
$820.00K
Y-mAbs Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$19.52M
-14.4%
Gross Profit
$16.86M
-14.8%
Gross Margin
86.37%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
104
N/A
Net Income
$3.24M
+65.0%
EBITDA
$5.60M
+41.8%
Quarterly Fundamentals
Net Cash
$59.17M
-22.7%
Accounts Receivable
$15.74M
-58.8%
Inventory
$9.72M
+14.4%
Long Term Debt
$2.64M
+510.6%
Short Term Debt
$486.00K
-42.3%
Return on Assets
-18.96%
N/A
Return on Invested Capital
-28.27%
N/A
Free Cash Flow
$1.65M
+454.0%
Operating Cash Flow
$1.65M
+454.0%